BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Rating of “Buy” from Brokerages

BioLife Solutions, Inc. (NASDAQ:BLFS) has been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $29.00.

A number of equities analysts have recently commented on BLFS shares. KeyCorp raised their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Benchmark restated a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, TD Cowen upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

BioLife Solutions Stock Down 1.2 %

Shares of BLFS stock opened at $26.27 on Tuesday. BioLife Solutions has a one year low of $14.50 and a one year high of $28.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The stock has a fifty day moving average price of $25.35 and a 200 day moving average price of $23.99. The stock has a market cap of $1.22 billion, a P/E ratio of -24.78 and a beta of 1.91.

Insider Activity at BioLife Solutions

In other news, EVP Aby J. Mathew sold 25,000 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $21.17, for a total transaction of $529,250.00. Following the sale, the executive vice president now owns 302,046 shares in the company, valued at approximately $6,394,313.82. This represents a 7.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 64,259 shares of company stock valued at $1,424,708 in the last three months. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLFS. Mark Sheptoff Financial Planning LLC acquired a new stake in BioLife Solutions in the 3rd quarter valued at about $28,000. Isthmus Partners LLC grew its stake in shares of BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of BioLife Solutions in the third quarter valued at approximately $57,000. GAMMA Investing LLC raised its position in BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in BioLife Solutions during the 2nd quarter worth $122,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.